Pipeline therapies for neovascular age related macular degeneration
Abstract Age related macular degeneration (AMD) is the most common cause of vision loss in the elderly population. Neovascular AMD comprises 10% of all cases and can lead to devastating visual loss due to choroidal neovascularization (CNV). There are various cytokine pathways involved in the formati...
Main Authors: | Sruthi Arepalli, Peter K. Kaiser |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-10-01
|
Series: | International Journal of Retina and Vitreous |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40942-021-00325-5 |
Similar Items
-
Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration
by: Reem H. ElSheikh, et al.
Published: (2022-11-01) -
LRG1 Expression Is Elevated in the Eyes of Patients with Neovascular Age-Related Macular Degeneration
by: Lucia Mundo, et al.
Published: (2021-08-01) -
Intravitreal Brolucizumab in Patients with Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
by: Ashwin Gupta, et al.
Published: (2022-01-01) -
Experimental Models in Neovascular Age Related Macular Degeneration
by: Olivia Rastoin, et al.
Published: (2020-06-01) -
A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with Lucentis® in patients with neovascular age-related macular degeneration
by: Ramandeep Singh, et al.
Published: (2022-01-01)